Aridis Pharmaceuticals, Inc. Contracts & Agreements
37 Contracts & Agreements
- Business Finance (26 contracts)
- Business Operations (2)
- Intellectual Property (5)
- Mergers & Acquisitions (1)
- Real Estate (1)
- Uncategorized (2)
- Form of Securities Purchase Agreement (Filed With SEC on June 27, 2024)
- Form of Securities Purchase Agreement (Filed With SEC on July 21, 2023)
- Form of Warrant (Filed With SEC on July 21, 2023)
- Form of Securities Purchase Agreement (Filed With SEC on June 27, 2023)
- Form of Pre-Funded Warrant (Filed With SEC on June 27, 2023)
- Form of Warrant (Filed With SEC on June 27, 2023)
- Note Purchase Agreement dated as of April 26, 2023 (Filed With SEC on May 1, 2023)
- Form of Secured Promissory Note (Filed With SEC on May 1, 2023)
- Security Agreement dated as of April 26, 2023 (Filed With SEC on May 1, 2023)
- Form of Securities Purchase Agreement (Filed With SEC on March 15, 2023)
- Form of Securities Purchase Agreement (Filed With SEC on December 12, 2022)
- Form of Securities Purchase Agreement (Filed With SEC on October 5, 2022)
- Form of Warrant (Filed With SEC on October 5, 2022)
- Form of Pre-Funded Warrant (Filed With SEC on October 5, 2022)
- At-the-Market Sales Agreement, dated January 19, 2022 by and between the Company and Virtu Americas LLC (Filed With SEC on January 19, 2022)
- Security Agreement dated as of November 23, 2021 (Filed With SEC on November 30, 2021)
- Note Purchase Agreement dated as of November 23, 2021 (Filed With SEC on November 30, 2021)
- Form of Secured Promissory Note (Filed With SEC on November 30, 2021)
- Amendment No. 1 to the License Agreement between Medimmune Limited and Aridis Pharmaceuticals, Inc. dated August 9, 2021 (Filed With SEC on August 12, 2021)
- Form of Securities Purchase Agreement (Filed With SEC on August 4, 2021)
- Form of Pre-Funded Common Stock Purchase Warrant (Filed With SEC on August 4, 2021)
- Form of Common Stock Purchase Warrant (Filed With SEC on August 4, 2021)
- License Agreement between Medimmune Limited and Aridis Pharmaceuticals, Inc. dated as of July 12, 2021 (Filed With SEC on July 19, 2021)
- Form of Securities Purchase Agreement, dated March 15, 2021, by and between Aridis Pharmaceuticals, Inc. and the Purchasers (Filed With SEC on March 15, 2021)
- Exclusive License Agreement dated September 10, 2020 by and between Aridis Pharmaceuticals, Inc. and UAB Research Foundation (Filed With SEC on November 23, 2020)
- Office Lease dated October 14, 2020 by and between Aridis Pharmaceuticals, Inc. and Boccardo Corporation (Filed With SEC on October 20, 2020)
- Form of Securities Purchase Agreement, dated October 13, 2020, by and between Aridis Pharmaceuticals, Inc. and the Purchasers (Filed With SEC on October 14, 2020)
- Form of Series A Warrant (Filed With SEC on October 14, 2020)
- Form of Series B Warrant (Filed With SEC on October 14, 2020)
- Description of the Registrant's Securities registered pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on April 8, 2020)
- License, Development and Commercialization Agreement between Aridis Pharmaceuticals, Inc. and Serum AMR Products, entered into as of September 27, 2019 (Filed With SEC on October 3, 2019)
- Stock Subscription Agreement, dated July 19, 2019 (Filed With SEC on July 30, 2019)
- Option Agreement for Exclusive Product and Platform Technology License between Aridis Pharmaceuticals, Inc. and Serum International BV, dated July 16, 2019 (Filed With SEC on July 30, 2019)
- Amendment No. 1 to the Agreement between the Registrant and the Cystic Fibrosis Foundation Therapeutics, Inc., effective November 26, 2018 (Filed With SEC on March 28, 2019)
- Amended and Restated Technology License and Collaboration Agreement, by and between Shenzen Arimab BioPharmaceutical Co., Ltd. and the Company, effective August 6, 2018 (Filed With SEC on September 26, 2018)
- Amendment to the Joint Venture Contract in respect of Shenzen Arimab BioPharmaceutical Co., Ltd., by and between Shenzen Hepalink Pharmaceutical Group Co. and the Company,... (Filed With SEC on September 26, 2018)
- Aridis Pharmaceuticals, Inc. [] Shares Common Stock (par value $0.001 per share) Underwriting Agreement (Filed With SEC on August 6, 2018)
